ZSZhihua She

Zhihua She

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhihua She has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Dangang Shangguan

    Department of Pharmacy, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People’s Republic of China

    1 shared publication
  • Dehua Liao

    Department of Pharmacy, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People’s Republic of China

    1 shared publication
  • Honglin Zhu

    Rheumatology and Immunology Department, Xiangya Hospital, Central South University, Changsha, Hunan, China

    1 shared publication
  • Jiang Zhu

    Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China

    1 shared publication
  • Jinyu Ning

    Department of Pharmacy, Hunan Provincial Maternal and Child Health Care Hospital, Changsha, Hunan, China

    1 shared publication
  • Jiwen Zhang

    Department of Pharmacy, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People’s Republic of China

    1 shared publication

Latest Publications

  • Open Access

    Proteomic and metabolomic analysis of serum in women infected with COVID-19 during late pregnancy

    by Yi Zheng, Jinyu Ning, Jiang Zhu, Honglin Zhu, Zhihua She, Pei Cai

    Introduction: To investigate the alterations of serum proteins and metabolomics in women infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at the end of pregnancy and their potential effects on fetal development.Methods: The corona virus disease 2019 (COVID-19) group (n=31) included women in the third trimester diagnosed with SARS-CoV-2 infection and who delivered, while the control group (n=30) comprised uninfected women in the same gestational period. This study applied data-independent acquisition (DIA) proteomics and ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF-MS) metabolomics to analyze serum samples from two groups of full-term pregnant women. Serum samples in the control group were collected one week before delivery, while those in the COVID-19 group were collected within two days after the onset of fever. The differences between groups were compared by bioinformatics data analysis. For proteins and metabolites exhibiting a significant association with SARS-CoV-2, metabolic pathway enrichment was performed utilizing MetaboAnalyst 6.0, and the possible targets and pathways of SARS-CoV-2 infection in women in late pregnancy were plotted.Results: The incidence of cesarean section, postpartum reproductive tract infection, and fetal distress were significantly higher in the COVID-19 group compared to the control group. Differential proteomic analysis revealed the regulation of proteins such as SAA1, SAA2, IPO7, WDR19, and BAZ1A, which were involved in processes such as visual, skin and limb development. Metabolomics analysis revealed key altered metabolites, including 1-(7-methoxy-2-oxo-2H-chromen-8-yl)-3-methyl-2-oxobutylacetate, 5-(hydroxymethyl) -4-methoxy-2,5-dihydrofuran-2-one, and cyclocytidine, which were involved in the riboflavin metabolism, the phenylalanine, tyrosine and tryptophan biosynthesis, and the arginine biosynthesis. Integrative analysis of proteomic and metabolomic revealed significant disruptions in metabolic pathways, including arginine biosynthesis, steroid hormone biosynthesis, and fatty acid degradation.Conclusions: This study revealed the main proteomic and metabolic effects of SARS-CoV-2 infection on women in the third trimester of pregnancy. Our comprehensive omics data elucidating the molecular mechanisms underlying SARS-CoV-2 infection in women during late pregnancy. These findings offer novel insights and potential targets for future investigations into the impact of SARS-CoV-2 infection on maternal and infant health.


  • Open Access

    Recent Advances in the Management of Adverse Events Associated with Lorlatinib

    by Dehua Liao, Jiwen Zhang, Ting Yan, Shanshan Chen, Wei Li, Dangang Shangguan, Zhihua She

    As a novel third-generation ALK tyrosine kinase inhibitor (TKI), lorlatinib has shown excellent systemic and intracranial activity in non-small cell lung cancer (NSCLC) patients who carry sensitizing ALK-activating mutations and progress on first- and second-generation TKIs. In comparison with other ALK-TKIs, lorlatinib has a unique safety profile for hyperlipidemia and central nervous system adverse events. Lorlatinib-induced adverse events are well tolerated, permanent discontinuations are rarely reported, and dose modifications and/or standard medical therapy are useful for the management of adverse events. Our present study reviews the safety profile of lorlatinib as well as the relevant management strategies. Our present study aims to provide a practical guide for the scientific management and application of lorlatinib.